Based On The R&D Syrength Of Guilinsanjin Related Diversification Strategy Research

By the international pharmaceutical companies to consolidate the core competitive strategy together with the strategy of diversifying driven,the pharmaceutical enterprises in our country are also continuously explore the road of diversification development and in order to strengthen the core competitiveness through diversification,occupies a place in the competition in the medical market.Diversified development has opened up a new market for the enterprise,bring new profit model,as a new profit growth point of enterprise,but also enhanced the competitiveness of enterprises in the industry.Diversity related diversification and unrelated diversification business types,related diversification through the sharing of resources transfer core competitive ability,attain the goal of occupy more market share.Research and development is the core competitiveness of high and new technology enterprise,is related diversification based,r&d investment and corporate performance is positively related to relationship,increase investment in research and development activities,can shorten the time of the new products into the market.Often implement diversification strategy is successful pharmaceutical enterprise in R&D of core technology as the key to development,carry out all that is associated with the core technology around the center of business and related business unit and through the research and development of core technology closely linked in a whole.Research and development of core technology as the core competitiveness is the basis of the pharmaceutical enterprises to carry out the strategy of related diversification and strong security,enterprises can revolve around the core technology,increase investment in research and development,and promote the implementation of the strategy of related diversification.This article selects cases of guilin sanjin group as the research object,firstly introduces in this paper,diversified involved r&d and related concepts and synergistic effect,and so on,then describes China's r&d investment in the pharmaceutical industry and guilin sanjin group and the present condition of the related diversification,then combining theory with guilin sanjin pharmaceutical industry will related indicators such as r&d,diversity index,return on assets,and so on were analyzed.Analysis shows that the related diversification and r&d spending has a positive interaction effect.According to the set of guilin sanjin health related diversification strategy,analysis the advantages and disadvantages in the process of implementing diversification,opportunities and threats,and finally puts forward four Suggestions:first,play advantage,relying on the brand leading products share the synergies,keep r&d sustainability to ensure competitive advantage;Second,avoid disadvantage,risk control policy,strengthen the marketing channel management;Third,grasps the opportunity,with the aid of electricity to extend the related diversified industrial chain,with big health trends to consolidate main business;Fourth,to respond to threats,ensure pharmaceutical quality,strengthen core products and improve the curative effect.